Boston, MA 05/29/2013 (wallstreetpr) – In Tuesday’s trading session, shares of BG Medicine, Inc (NASDAQ:BGMD) rose by 13.37%. The opening price $1.90 touched an intraday high of $2.17 before dipping to $1.82 per share. Over 1.73M shares were traded in Tuesday’s trading session which was higher than the average volume of 0.118M that was measured over a period of 30 days
On May 28, the company announced that the latest clinical data for the BGM Galectin test used in heart disease will be presented at the 2013 European Society of Cardiology Heart Failure Congress. This is going to be held in Lisbon, Portugal. As part of the highlights, a late-breaking oral presentation of results was put forth from the Aldo-DHF Biomarker Sub-study. This demonstrated the merits of galectin-3 testing in assessing functional capacity as well as clinical prognosis. This is used in patients who have been diagnosed with Heart Failure with Preserved Ejection Fraction.
BG Medicine, Inc (NASDAQ:BGMD) is a life sciences company. It focuses on discovering, developing and commercializing various cardiovascular diagnostics. These are meant to addresses any unmet medical needs. BGMD focuses on numerous blood-based tests that it carries out as part of its studies. CardioSCORE, is the company’s lead product candidate. It is currently in the development stage. It is a multi-analyte biomarker based blood-test that is conducted to test for atherothrombotic cardiovascular disease. This disease is also referred to as vulnerable plaque. In 2011 March, BG Medicine, Inc (NASDAQ:BGMD) signed a supply agreement with a company named Health Diagnostic Laboratory, Inc.
